Verastem (VSTM) Total Non-Current Liabilities (2012 - 2026)
Verastem's quarterly Total Non-Current Liabilities came in at $146.0 million in Q1 2026, up 33.5% year-on-year from $109.4 million in Q1 2025, and down 4.93% quarter-over-quarter from $153.6 million in Q4 2025.
Verastem has reported Total Non-Current Liabilities for 12 years, with the latest figure at $146.0 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 33.5% year-over-year to $146.0 million; the trailing twelve-month figure through Mar 2026 stood at $146.0 million (up 33.5% YoY), and the FY2025 full-year result was $153.6 million, up 112.65% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $146.0 million, down from $153.6 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $153.6 million in Q4 2025, with the low at $68.0 million in Q3 2024.
- Average Total Non-Current Liabilities over 4 years is $114.7 million, with a median of $126.7 million recorded in 2025.
- Year-over-year, Total Non-Current Liabilities decreased 5.21% in 2024 and surged 112.65% in 2025.
- Tracing VSTM's Total Non-Current Liabilities over 4 years: stood at $71.8 million in 2023, then climbed by 0.65% to $72.2 million in 2024, then surged by 112.65% to $153.6 million in 2025, then decreased by 4.93% to $146.0 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $146.0 million (Q1 2026), $153.6 million (Q4 2025), and $144.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Verastem | 425.60 Mn | 243.93 Mn | 15.90 Mn | 146.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146.03 Mn |
| Dec 31, 2025 | 153.60 Mn |
| Sep 30, 2025 | 144.09 Mn |
| Jun 30, 2025 | 152.66 Mn |
| Mar 31, 2025 | 109.39 Mn |
| Dec 31, 2024 | 72.23 Mn |
| Sep 30, 2024 | 68.02 Mn |
| Sep 30, 2023 | 71.76 Mn |
| Jun 30, 2020 | 83.29 Mn |
| Mar 31, 2020 | 84.30 Mn |
| Dec 31, 2019 | 137.00 Mn |
| Sep 30, 2019 | 170.21 Mn |
| Jun 30, 2019 | 168.73 Mn |
| Mar 31, 2019 | 154.41 Mn |
| Dec 31, 2018 | 151.81 Mn |
| Sep 30, 2018 | 74.98 Mn |
| Jun 30, 2018 | 45.65 Mn |
| Mar 31, 2018 | 29.76 Mn |
| Dec 31, 2017 | 31.96 Mn |
| Sep 30, 2017 | 21.95 Mn |
| Jun 30, 2017 | 13.36 Mn |
| Mar 31, 2017 | 15.48 Mn |
| Dec 31, 2016 | 11.33 Mn |
| Sep 30, 2016 | 6.22 Mn |
| Jun 30, 2016 | 5.93 Mn |
| Mar 31, 2016 | 6.12 Mn |
| Dec 31, 2015 | 10.11 Mn |
| Sep 30, 2013 | 5.71 Mn |
| Dec 31, 2012 | 2.40 Mn |